within Pharmacolibrary.Drugs.ATC.C;

model C01DX22
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.93,
    Cl             = 2.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0448,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0056500000000000005,
    Tlag           = 60.0,            
    Vdp             = 0.0247,
    k12             = 2.69,
    k21             = 2.69
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01DX22</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Vericiguat is a soluble guanylate cyclase (sGC) stimulator used in the treatment of symptomatic chronic heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and heart failure hospitalization. It is approved for use in several countries, including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults with chronic heart failure after oral administration of vericiguat at steady-state.</p><h4>References</h4><ol><li><p>Janssen, W, et al., &amp; Gerisch, M (2022). Pharmacokinetics and mass balance of vericiguat in rats and dogs and distribution in rats. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 52(5) 453–462. DOI:<a href=&quot;https://doi.org/10.1080/00498254.2022.2082899&quot;>10.1080/00498254.2022.2082899</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35616579/&quot;>https://pubmed.ncbi.nlm.nih.gov/35616579</a></p></li><li><p>Campbell, N, et al., &amp; Frey, K (2022). Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure. <i>The Annals of pharmacotherapy</i> 56(5) 600–608. DOI:<a href=&quot;https://doi.org/10.1177/10600280211041384&quot;>10.1177/10600280211041384</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34431706/&quot;>https://pubmed.ncbi.nlm.nih.gov/34431706</a></p></li><li><p>Fritsch, A, et al., &amp; Becker, C (2024). Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat. <i>Clinical pharmacokinetics</i> 63(6) 751–771. DOI:<a href=&quot;https://doi.org/10.1007/s40262-024-01384-1&quot;>10.1007/s40262-024-01384-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38916717/&quot;>https://pubmed.ncbi.nlm.nih.gov/38916717</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01DX22;
